AstraZeneca (ADR)
Develops oncology-led medicines spanning rare diseases, cardiovascular care, metabolism, respiratory disease, and immunology.
$161.79
After-hours close−0.89 (−0.55%)
At close$162.68(−1.12%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 52.03%806.53M sharesInsiders 0.00%19.3K sharesOther 47.97%743.45M shares
Shares outstanding 1.55B · Float 1.54B · 99.6% free float
Institutions13F, as of Jun 30, 2026
1,514 holders · 806.53M shares · 283 new positions · 795 increased · 478 reduced · 136 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Investor AB | 51.59M | 3.33% | 0 | Aug 14, 2026 |
| Vanguard Capital Management LLC | 45.39M | 2.93% | +346.0K | Aug 13, 2026 |
| Capital International Investors | 34.58M | 2.23% | +183.1K | Aug 12, 2026 |
| Norges Bank | 33.86M | 2.18% | +33.86Mnew | Aug 12, 2026 |
| Capital World Investors | 30.08M | 1.94% | +1.81M | Aug 12, 2026 |
| FMR LLC | 28.90M | 1.86% | −706.5K | Aug 13, 2026 |
| Wellington Management Group LLP | 28.54M | 1.84% | +4.79M | Aug 14, 2026 |
| Legal & General Group PLC | 25.75M | 1.66% | −99.7K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 7.60% | 13G | Apr 23, 2025 ↗ | |
| Vanguard Capital Management | 5.02% | 77.97M | 13G | Apr 28, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Mani Sharma | officer: SVP, Group Controller | 19.3K | 0.00% | Aug 7, 2026 |
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| May 20, 2026 | Mani Sharmaofficer: See Remarks | Sale | 11,893 | $185.78 | 19,262 |
CongressHouse and Senate disclosures
Not reported.